Paper39212337
Utilizing an acute hyperthermia-induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome.
Mensah JA and 6 others. Epilepsia, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Utilizing an acute hyperthermia-induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome. Papers, record 39212337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39212337
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Utilizing an acute hyperthermia-induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Epilepsies, Myoclonic | Major topic |
| Disease Models, Animal | Major topic |
| Clobazam | Major topic |
| Anticonvulsants | Major topic |
| Valproic Acid | Major topic |
| Dioxolanes | Major topic |
| Cannabidiol | Major topic |
| Hyperthermia | Major topic |
| Animals | |
| Mice | |
| Drug Therapy, Combination | |
| NAV1.1 Voltage-Gated Sodium Channel | |
| Seizures | |
| Dose-Response Relationship, Drug | |
| Mice, Transgenic | |
| Male | |
| Fenfluramine |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 75N95022C00007 | NIDA NIH HHS | United States | PubMed | |
| HHSN271201600048C | NIDA NIH HHS | United States | PubMed | |
| Donald R. Gehlert Fellowship, University of Utah College of Pharmacy | PubMed | |||
| HHS 75N95022C00007 | National Institute of Neurological Disorders and Stroke, Epilepsy Therapy Screening Program, National Institutes of Health, and Department of Health and Human Services | PubMed |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38427284 | Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. | Epilepsia Open | 2024 | https://conductscience.org/library/papers/38427284 | PubMed |
| 2 | 27264138 | Treatment of Dravet Syndrome. | Can J Neurol Sci | 2016 | https://conductscience.org/library/papers/27264138 | PubMed |
| 3 | 31519475 | Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures. | Epilepsy Behav | 2019 | https://conductscience.org/library/papers/31519475 | PubMed |
| 4 | 30509294 | Reviewing the role of healthy volunteer studies in drug development. | J Transl Med | 2018 | https://conductscience.org/library/papers/30509294 | PubMed |
| 5 | 26651971 | Cannabinoids and Cytochrome P450 Interactions. | Curr Drug Metab | 2016 | https://conductscience.org/library/papers/26651971 | PubMed |
| 6 | 22743350 | Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. | Ther Drug Monit | 2012 | https://conductscience.org/library/papers/22743350 | PubMed |
| 7 | 31862249 | Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. | Lancet | 2019 | https://conductscience.org/library/papers/31862249 | PubMed |
| 8 | 31790543 | Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. | JAMA Neurol | 2020 | https://conductscience.org/library/papers/31790543 | PubMed |
| 9 | 30638257 | Ascertaining the epidemiology, patient flow and disease management for Dravet syndrome in Spain. | Rev Neurol | 2019 | https://conductscience.org/library/papers/30638257 | PubMed |
| 10 | 32054370 | Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. | Expert Opin Drug Metab Toxicol | 2020 | https://conductscience.org/library/papers/32054370 | PubMed |
| 11 | 34882995 | Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe. | Epilepsia Open | 2022 | https://conductscience.org/library/papers/34882995 | PubMed |
| 12 | 11736863 | In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). | Br J Clin Pharmacol | 2001 | https://conductscience.org/library/papers/11736863 | PubMed |
| 13 | 12954800 | Interaction of antiepileptic drugs with human P-glycoprotein in vitro. | J Pharmacol Exp Ther | 2003 | https://conductscience.org/library/papers/12954800 | PubMed |
| 14 | 21463272 | The core Dravet syndrome phenotype. | Epilepsia | 2011 | https://conductscience.org/library/papers/21463272 | PubMed |
| 15 | 15526956 | Severe myoclonic epilepsy in infancy: toward an optimal treatment. | J Child Neurol | 2004 | https://conductscience.org/library/papers/15526956 | PubMed |
| 16 | 31549357 | Recent Advances in the Drug Treatment of Dravet Syndrome. | CNS Drugs | 2019 | https://conductscience.org/library/papers/31549357 | PubMed |
| 17 | 22718676 | Dose-finding designs: the role of convergence properties. | Int J Biostat | 2011 | https://conductscience.org/library/papers/22718676 | PubMed |
| 18 | 34093420 | Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome. | Front Neurol | 2021 | https://conductscience.org/library/papers/34093420 | PubMed |
| 19 | 26183863 | Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes. | Brain Dev | 2016 | https://conductscience.org/library/papers/26183863 | PubMed |
| 20 | 34130255 | Evaluation of lorcaserin as an anticonvulsant in juvenile Fmr1 knockout mice. | Epilepsy Res | 2021 | https://conductscience.org/library/papers/34130255 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40972134 | Analysis of seven selected cannabinoids in human plasma highlighting matrix and solution stability assessments. | J Anal Toxicol | 2026 | https://conductscience.org/library/papers/40972134 | PubMed |
| 40586768 | Development of a preclinical testing platform for clinically relevant therapy for Dravet syndrome. | Epilepsia | 2025 | https://conductscience.org/library/papers/40586768 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39212337
GET https://conductscience.org/api/papers/v1/39212337/references?page=2